Skip to main content

Table 4 Adverse events associated with artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) treatment in Owando health facilities

From: Malaria burden and anti-malarial drug efficacy in Owando, northern Congo

Adverse events ASAQ (n/N; %) AL (n/N; %)a
Day 1 Day 2 Day 3 Total Day 1 Day 2 Total
Asthenia 4/61; 5.6 6/61; 9.8 3/59; 5.1 13/181; 7.2 1/57; 1.8 1/56; 1.8 2/113; 1.8
Vomiting 3/61; 4.9 0/61; 0 0/59; 0 3/181; 1.6 1/57; 1.8 0/56; 0 1/113; 0.9
Headache 0/61; 0 1/61; 1.6 0/59; 0 1/181; 0.6 0/57; 0 0/56; 0 0/113; 0
Urticaria 0/61; 0 1/61; 1.6 0/59; 0 1/181; 0.6 0/57; 0 0/56; 0 0/113; 0
Abdominal pain 1/61; 1.6 1/61; 1.6 1/59; 1.7 3/181; 1.7 0/57; 0 0/56; 0 0/113; 0
Total 8/61; 13.1 9/61; 14.8 4/59; 6.8 21/181; 11.6 2/57; 0.7 1/56; 0.4 3/113: 2.7
  1. N number of patients followed up, n number of patients with adverse events
  2. aThere were no reported adverse events on day 3 in the AL group
  3. There was a statistically significant difference (p = 0.004) in the proportions of ASAQ- and AL-treated patients reporting adverse events